The combination of these antibodies with KRAS inhibitors has shown improved control of tumor compared to monotherapy,[11, 59, 60] and is one of the most promising areas of exploration at this stage, with multiple clinical trials currently underway (Figure7 and Table3). Here, KRAS is linked to neoplasm.